Nicholas Grund, Chief Commercial Officer of Akebia Therapeutics ($AKBA), made two open market sales of company shares in the past year, totaling $117,912. His most recent sale occurred on February 2, 2026. These transactions rank 9,333rd among 11,678 insiders by sale value, well below the average of $8.6 million across 6.37 transactions per insider. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | S | Common Stock | 53585 | $1.39 | 592,994.0000 | 274,372,722 | 8.29% | 0.02% |
| Feb. 2, 2026 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | S | Common Stock | 31244 | $1.39 | 561,750.0000 | 274,372,722 | 5.27% | 0.01% |
| Jan. 30, 2026 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | A | Common Stock | 204000 | $0.00 | 646,579.0000 | 274,372,722 | 46.09% | 0.07% |
| Jan. 30, 2026 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | A | Stock Option (Right to buy) | 320000 | $0.00 | 320,000.0000 | 274,372,722 | 9999.99% | 0.12% |
| Jan. 31, 2025 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | A | Common Stock | 194900 | $0.00 | 498,200.0000 | 210,946,658 | 64.26% | 0.09% |
| Feb. 3, 2025 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | S | Common Stock | 55621 | $2.10 | 442,579.0000 | 210,946,658 | 11.16% | 0.03% |
| Jan. 31, 2025 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | A | Stock Option (Right to buy) | 292300 | $0.00 | 292,300.0000 | 210,946,658 | 9999.99% | 0.14% |
| Jan. 31, 2024 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | A | Stock Option (Right to buy) | 454950 | $0.00 | 454,950.0000 | 187,465,448 | 9999.99% | 0.24% |
| Jan. 31, 2024 | Akebia Therapeutics, Inc. | $AKBA | Grund Nicholas | Chief Commercial Officer | A | Common Stock | 303300 | $0.00 | 303,300.0000 | 187,465,448 | 9999.99% | 0.16% |